The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline

Author： Vinkers Christiaan H   Mirza Naheed R   Olivier Berend   Kahn René S  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.10, 2010-10, pp. : 1217-1233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia

By  

Current Neuropharmacology, Vol. 3, Iss. 1, 2005-01 ,pp. : 45-62

Bentham Science Publishers

Access to resources Recommend Favorite

GABA System as a Target for New Drugs

By  

Current Medicinal Chemistry, Vol. 21, Iss. 28, 2014-09 ,pp. : 3294-3309

Bentham Science Publishers

Access to resources Recommend Favorite

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

By Coyle Joseph   Tsai Guochuan  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 32-38

Springer Publishing Company

Access to resources Recommend Favorite

Altered Cortical GABA Neurotransmission in Schizophrenia: Insights into Novel Therapeutic Strategies

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 8, 2012-06 ,pp. : 1557-1562

Bentham Science Publishers

Access to resources Recommend Favorite

Cellular FLICE-inhibitory protein: an attractive therapeutic target?

By Micheau Olivier  

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 4, 2003-08 ,pp. : 559-573

Informa Healthcare

Access to resources Recommend Favorite